Chemotherapy-induced peripheral neurotoxicity (CIPN): an update
The peripheral nervous system can be vulnerable to the toxic action of several drugs since it
is not protected as effectively as the central nervous system from noxious exogenous agents …
is not protected as effectively as the central nervous system from noxious exogenous agents …
Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines
A Stenzl, NC Cowan, M De Santis, MA Kuczyk… - European urology, 2011 - Elsevier
CONTEXT: New data regarding treatment of muscle-invasive and metastatic bladder cancer
(MiM-BC) has emerged and led to an update of the European Association of Urology (EAU) …
(MiM-BC) has emerged and led to an update of the European Association of Urology (EAU) …
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
There have been no major advances for the treatment of metastatic urothelial bladder
cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient …
cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient …
Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer
JA Witjes, T Lebret, EM Compérat, NC Cowan… - European urology, 2017 - Elsevier
Context Invasive bladder cancer is a frequently occurring disease with a high mortality rate
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …
despite optimal treatment. The European Association of Urology (EAU) Muscle-invasive and …
Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced …
J Bellmunt, C Théodore, T Demkov… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Vinflunine (VFL) is a new microtubule inhibitor that has activity against transitional
cell carcinoma of urothelial tract (TCCU). We conducted a randomized phase III study of VFL …
cell carcinoma of urothelial tract (TCCU). We conducted a randomized phase III study of VFL …
Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance
EA Perez - Molecular cancer therapeutics, 2009 - AACR
Microtubules are important cellular targets for anticancer therapy because of their key role in
mitosis. Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones …
mitosis. Microtubule inhibitors (MTI) such as taxanes, vinca alkaloids, and epothilones …
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
J Bellmunt, TK Choueiri, R Fougeray… - Journal of Clinical …, 2010 - ascopubs.org
Purpose The present study sought to identify pretreatment prognostic factors for overall
survival (OS) in patients with metastatic transitional cell carcinoma of the urothelial tract …
survival (OS) in patients with metastatic transitional cell carcinoma of the urothelial tract …
New anticancer agents: recent developments in tumor therapy
Increasing recurrence of mammalian tumors and severe side-effects of chemotherapeutic
agents reduce the clinical efficacy of a large variety of anticancer agents that are currently …
agents reduce the clinical efficacy of a large variety of anticancer agents that are currently …
A single‐arm, multicenter, open‐label phase 2 study of lapatinib as the second‐line treatment of patients with locally advanced or metastatic transitional cell …
C Wülfing, JPH Machiels, DJ Richel, MO Grimm… - Cancer, 2009 - Wiley Online Library
BACKGROUND: The treatment of recurrent transitional cell carcinoma (TCC) remains an
unmet clinical need. This study assessed lapatinib, a dual tyrosine kinase inhibitor of …
unmet clinical need. This study assessed lapatinib, a dual tyrosine kinase inhibitor of …
Second line chemotherapy for advanced and metastatic urothelial carcinoma: vinflunine and beyond—a comprehensive review of the current literature
C Oing, M Rink, K Oechsle, C Seidel… - The Journal of …, 2016 - Elsevier
Purpose We comprehensively reviewed current efforts and advances in the field of
chemotherapeutic and biologically targeted treatment options after the failure of cisplatin …
chemotherapeutic and biologically targeted treatment options after the failure of cisplatin …